drugset / Trial / NCT07092566
R.E.C.K vs Exparel in Robotic Nephrectomy
Phase 3
Recruiting
170 enrolled
Wake Forest University Health Sciences
Atrium Health Levine Cancer Institute · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of the study is to evaluate the efficacy of R.E.C.K (ropivacaine epinephrine clonidine ketorolac) vs Exparel during robotic partial and radical nephrectomy in a single institution, prospective, randomized trial. The study will evaluate post operative Numerical Rating Score (NRS) pain scores, post operative pain medication intake (opioids and over-the-counter pain medicines) and length of stay across the two patient cohorts. The findings will help to inform whether the increased cost of Exparel when compared to R.E.C.K is justified.
Timeline
- Start
- 2025-11-14
- Primary completion
- 2027-10
- Completion
- 2027-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bupivacaine | Other / unclassified | 100 ml | Intramuscular |
| Comparator | Clonidine | Other / unclassified | 0.04 mg | Intramuscular |
| Comparator | Epinephrine | Other / unclassified | 0.25 mg | Intramuscular |
| Comparator | Ketorolac | Other / unclassified | 15 mg | Intramuscular |
| Comparator | Ropivacaine | Other / unclassified | 123 mg | Intramuscular |